Atrial fibrillation (AF) is an arrhythmia that can occur as the result of numerous different
pathophysiological processes in the atria. Some aspects of the morphological and …

The National Heart, Lung, and Blood Institute convened an expert panel April 28 to 29,
2008, to identify gaps and recommend research strategies to prevent atrial fibrillation (AF) …

Inadequacies in current therapies for atrial fibrillation have made new drug development
crucial. Conventional antiarrhythmic drugs increase the risk of ventricular proarrhythmia. In …

Statins inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, the rate-
limiting enzyme in cholesterol biosynthesis, which converts HMG-CoA to mevalonate …

Background—Several cardiovascular risk factors have been associated with the risk of atrial
fibrillation (AF). Limited and inconsistent evidence exists on the association of blood lipid …

Objectives: We studied the signal transduction of atrial structural remodeling that contributes
to the pathogenesis of atrial fibrillation (AF). Background: Fibrosis is a hallmark of …

Objective To examine whether statins can reduce the risk of atrial fibrillation. Design Meta-
analysis of published and unpublished results from larger scale statin trials, with comparison …

Atrial fibrillation (AF) is the most common arrhythmia in humans. It affects 5% of the
population over the age of 65 years and is projected to rise as the population ages …

Aims Increasing evidence supports a role for inflammation in promoting atrial fibrillation (AF)
and statins have anti-inflammatory effects that may be relevant for the prevention of AF …

Significance: Cardiovascular diseases (CVD) represent a major public health burden. High
low-density lipoprotein (LDL)-cholesterol is a recognized pathogenic factor for …